# Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

- Link: https://www.thailand-business-news.com/pr-news/deepening-collaboration-in-ai-powered-rd-acceleration-insilico-medicine-and-cms-announce-additional-collaborations-in-cns-diseases
- Published: 2026-07-13T07:30:00+07:00
- Author: PR Newswire

SHANGHAI, July 13, 2026 /PRNewswire/ — Insilico Medicine ("Insilico", 03696.HK),
a clinical-stage biotechnology company driven by generative artificial intelligence(
AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform
innovative company linking pharmaceutical innovation and commercialization with 
strong product lifecycle management capability, today announced an additional AI‑
empowered drug discovery collaboration targeting a mass-market indication in central
nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.

According to the collaboration agreement, the two parties will jointly advance the
co-development of the R&D program by combining Insilico Medicine’s validated AI 
platform and AI-enabled innovative drug discovery and development capabilities with
CMS’s experienced R&D team and deep therapeutic expertise. Insilico Medicine is 
eligible to receive **up to approximately 1.2 billion RMB in milestone payments 
plus royalties**. This partnership marks a deepening collaboration that leverages
both parties’ complementary strengths across the full value chain—from drug discovery
and clinical development to commercialization.

**Mr. Lam Kong, the Chairman, Chief Executive Officer, President and Executive Director
of CMS said:** "CMS is deeply impressed by Insilico Medicine’s capability and productivity
in AI drug discovery. We are happy to deepen our collaboration with Insilico Medicine.
Insilico Medicine’s leadership in AI drug discovery platforms and data-driven R&
D is strategically complementary to CMS’s capabilities in innovative R&D and clinical
translation. In addition, CMS has built solid strengths in clinical development 
systems and efficiency, regulatory submission expertise, and commercialization network
coverage. Our goal never changes: to accelerate the delivery of more clinically 
meaningful innovations to patients with greater speed and quality, better meeting
the growing clinical needs."

"We are delighted to establish another collaboration with China Medical System just
three months after our initial announcement," said **Feng Ren, PhD, Co-CEO and Chief
Scientific Officer of Insilico Medicine**. "Our existing partnership, announced 
earlier this year, has been seamless and productive since its inception. In this
new program, we value the input from the CMS commercialization team and are proud
of the innovative **Mechanism of Action (MoA)** identified by **PandaOmics**, which
streamlines the development of high-potential drugs, enhancing translational efficiency,
and accelerating the transition of molecules from ‘proof of concept’ to life-changing
patient therapies. We will continue to deepen our multi-dimensional collaboration
in pipeline and clinical strategy and global partnerships to provide patients with
more differentiated and accessible treatment options."

About CMS

CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical
innovation and commercialization with strong product lifecycle management capability,
dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative
products, and efficiently promotes the clinical research, development and commercialization
of innovative products, enabling the continuous transformation of scientific research
into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven
commercialization capabilities, extensive networks and expert resources, resulting
in leading academic and market positions for its major marketed products. CMS continues
to promote the in-depth development in its advantageous specialty fields, strengthening
the competitiveness of the Cardiovascular-Kidney-Metabolic/gastroenterology/ophthalmology/
skin health businesses, bringing economies of scale in specialty fields.

About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company
dedicated to integrating artificial intelligence and automation technologies to 
accelerate drug discovery, drive innovation in the life sciences, and extend health
longevity to people on the planet. The company was listed on the Main Board of the
Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities,
Insilico is delivering innovative drug solutions for unmet needs including fibrosis,
oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico
extends the reach of Pharma.AI across diverse industries, such as advanced materials,
agriculture, nutritional products and veterinary medicine. For more information,
please visit [www.insilico.com](http://www.insilico.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases ](http://www.prnasia.com/story/archive/5002018_CN02018_0?rand=184833)